…Baxter will receive Suppremol’s early-stage drug portfolio, notably its SM101 immunoregulatory treatment that has completed a Phase 2 study. Baxter also will operate Suppremol’s operations in Munich.
This program will end up with BXLT after BAX’s split-up.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”